{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:38:29Z","timestamp":1772815109694,"version":"3.50.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Despite advancements in treatment, unmet needs persist for patients with plaque psoriasis (PSO). This study characterized PSO patients who were initiating or switching biologic medications, with or without prior biologic use, and highlighted the unmet needs due to medication switches and concomitant treatments. The impact of biologic therapy initiation was assessed through changes in healthcare resource utilization (HCRU), sick leave, and disability pensions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study utilized electronic healthcare data of adult patients with PSO and reimbursed biologic medication purchases made between 2013 and 2021 in Finland. Patients were followed from the day of first biologic treatment purchase (first biological cohort) or switch (switchers) until 2022 or death\/loss of follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 2,437 patients with PSO and biologic medication purchases were investigated. Of this total, 14.2% (<jats:italic>n<\/jats:italic>\u202f=\u202f345) were switchers, and 85.8% (<jats:italic>n<\/jats:italic>\u202f=\u202f2,092) comprised the first biological cohort. Among the first biological cohort, 12.5% [95% confidence interval (CI): 11.1, 13.9] had switched to other biologic medications 1\u202fyear after initiation. Work absences started to accumulate before the initiation of the first medication in the first biological cohort, followed by a subsequent decrease, while the accumulation remained modest and linear in shape among the switchers. The proportion of patients aged &amp;lt;65 on disability pension was higher among the switchers compared to the first biological cohort (7.8% (<jats:italic>n<\/jats:italic>\u202f=\u202f27) and 6.6% (<jats:italic>n<\/jats:italic>\u202f=\u202f138), respectively). A total of 86 first biological patients (4.1%) and 11 (3.2%) switchers were receiving disability pension before the biologic treatment was initiated. The number of all-cause secondary healthcare outpatient contacts per year (11.1 vs. 7.4 per patient; <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001) and disease-related inpatient days (0.46 vs. 0.16 per patient; <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001) was lower 1\u202fyear after the initiation of biologic treatment in the first biological cohort compared to the time before biologic treatment. The decrease in the disease-related any-type contact cost per year for the first biological cohort was significant, from \u20ac2,098 (95% CI: 1,975, 2,221) to \u20ac1,094 (95% CI: 1,012, 1,176; <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001). No significant reduction was observed in the HCRU of switchers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study highlights the need for timely treatment and underscores the significant unmet needs among patients with PSO. Further studies are needed to evaluate the overall benefits of early utilization of highly effective treatments.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1605100","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T13:31:26Z","timestamp":1753191086000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A population-based registry study on psoriasis-associated burden of disease in Finland"],"prefix":"10.3389","volume":"12","author":[{"given":"Liisa","family":"Ukkola-Vuoti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Kl\u00e5vus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iiro","family":"Toppila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenni","family":"H\u00e4llfors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauri","family":"Veijalainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarja","family":"M\u00e4lk\u00f6nen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13690-020-00479-y","article-title":"Incentives for Danish healthcare management based on a pilot outcome-based, patient-centric management model in psoriasis and psoriatic arthritis: the non-interventional IMPROVE study","volume":"78","author":"Thomsen","year":"2020","journal-title":"Arch Public Health"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"743180","DOI":"10.3389\/fmed.2021.743180","article-title":"The global, regional, and National Burden of psoriasis: results and insights from the global burden of disease 2019 study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1159\/000499924","article-title":"Socioeconomic costs and health inequalities from psoriasis: a cohort study","volume":"235","author":"Thomsen","year":"2019","journal-title":"Dermatology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/acr.22492","article-title":"Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis","volume":"67","author":"Feldman","year":"2015","journal-title":"Arthritis Care Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1136\/annrheumdis-2016-210579","article-title":"Societal costs and patients\u2019 experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study","volume":"76","author":"Kristensen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12913-015-0752-0","article-title":"How much of the productivity losses among psoriasis patients are due to psoriasis","volume":"15","author":"Mustonen","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1007\/s10067-021-05713-8","article-title":"Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA\u2013a retrospective study of claims data from 2009 to 2020","volume":"40","author":"Merola","year":"2021","journal-title":"Clin Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1027347","DOI":"10.3389\/fmed.2022.1027347","article-title":"Early intervention in psoriasis: where do we go from here?","volume":"9","author":"Felix","year":"2022","journal-title":"Front Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"CD011535","DOI":"10.1002\/14651858.CD011535.pub3","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2340\/00015555-1485","article-title":"Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three Nordic countries","volume":"93","author":"Tennvall","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2217\/imt-2018-0131","article-title":"Biologics switch in psoriasis","volume":"11","author":"Wang","year":"2019","journal-title":"Immunotherapy"},{"key":"ref15","year":"2024"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"adv00886","DOI":"10.2340\/actadv.v103.3491","article-title":"Comorbidities and medication use in Finnish patients with psoriasis: a population-based registry study","volume":"103","author":"Vesikansa","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jaad.2008.02.048","article-title":"Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists","volume":"58","author":"Patel","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/CLEP.S314959","article-title":"Nordic health registry-based research: a review of health care systems and key registries","volume":"13","author":"Laugesen","year":"2021","journal-title":"Clin Epidemiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1374829","DOI":"10.3389\/fimmu.2024.1374829","article-title":"Healthcare resource utilization patterns in psoriasis patients using biologic and conventional treatments in Finland","volume":"15","author":"Vesikansa","year":"2024","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMoa2102383","article-title":"Finland: health system review","volume":"21","author":"Keskimaki","year":"2019","journal-title":"Health Syst Transit"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"ref22","author":"M\u00e4klin","year":"2017"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jaad.2016.01.048","article-title":"Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population","volume":"74","author":"Doshi","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2299598","DOI":"10.1080\/09546634.2023.2299598","article-title":"Real-world biologic treatment patterns and healthcare resource utilization in psoriasis patients using an insurance claims database in Japan","volume":"35","author":"Miyazaki","year":"2024","journal-title":"J Dermatol Treat"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ad.2014.10.001","article-title":"Treatment goals for psoriasis: should PASI 90 become the standard of care?","volume":"106","author":"Torres","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus Adalimumab in Plaque Psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1243843","DOI":"10.3389\/fmed.2023.1243843","article-title":"Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study\u2014IL PSO (Italian landscape psoriasis)","volume":"10","author":"Gargiulo","year":"2023","journal-title":"Front Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/north American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2147\/CCID.S90270","article-title":"Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis","volume":"8","author":"Rich-Garg","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref32","year":"2025"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1001\/jamacardio.2024.2859","article-title":"Exploring the link between genetic predictors of cardiovascular disease and psoriasis","volume":"9","author":"Ramessur","year":"2024","journal-title":"JAMA Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris \u2013 part 2: specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ejim.2006.07.005","article-title":"Epidemiology and natural history of Gaucher\u2019s disease","volume":"17","author":"Mehta","year":"2006","journal-title":"Eur J Intern Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2340\/00015555-2672","article-title":"Incidence and prevalence of psoriasis in Denmark","volume":"97","author":"Egeberg","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2014 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jdin.2021.02.003","article-title":"Societal impact for patients with psoriasis: a nationwide Swedish register study","volume":"3","author":"H\u00e4bel","year":"2021","journal-title":"JAAD Int"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1605100\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T13:31:27Z","timestamp":1753191087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1605100\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":39,"alternative-id":["10.3389\/fmed.2025.1605100"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1605100","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"article-number":"1605100"}}